tiprankstipranks
Trending News
More News >

Chimerix downgraded to Neutral from Outperform at Wedbush

Wedbush downgraded Chimerix (CMRX) to Neutral from Outperform with a price target of $8.55, up from $7, after the company agreed to be acquired by Jazz Pharmaceuticals (JAZZ) for $8.55 per share in cash, representing a total consideration of approximately $935M.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue